Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06801977

The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study

This retrospective case-control study aims to investigate the genetic mechanisms of primary Pulmonary Lymphoepithelioma-like Carcinoma, identify genetic susceptibility loci associated with its onset, and explore potential pathogenic genes, providing new insights for its etiological research.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Foshan First People's Hospital, Foshan, Guangdong, China

Loading trial locations.

About this study

Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare non-small cell lung cancer (NSCLC) that histologically resembles nasopharyngeal carcinoma (NPC) and predominantly affects the Asian population. Epstein-Barr virus (EBV) infection is a recognized pathogenic factor, and the regional prevalence of pLELC suggests that genetic susceptibility also plays an important role. However, no genetic studies on pLELC have been conducted, leaving its genetic etiology poorly understood. In this study, genotyping for all the subjects was performed by using Illumina Infinium Global Screening Array. Genome-wide association followed by meta-analysis was performed for pLELC cases and healthy controls. The primary objective of this study is to discover susceptibility genes that explain the genetic mechanisms of pLELC.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Case:

Inclusion criteria

The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma.

Exclusion criteria

The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease.

Controls:

Inclusion criteria

The subject is in good physical condition and has a stable level of consciousness;

Exclusion criteria

The subject has prevalent cancer; The subject has heavy cardiovascular, liver, or kidney disease.

Treatment and study plan

Genome-wide genotyping

Genetic

Whole blood from the participants was used to extract DNA for genotyping.

Primary outcomes

  1. the occurrence of Pulmonary Lymphoepithelioma-like Carcinoma

    Time frame: The enrollment of the participants

    pathological diagnosis of Pulmonary Lymphoepithelioma-like Carcinoma

Study contacts

Contact information is provided by the study sponsor or research team.

Tong-Min Wang, PhD

CONTACT

[email protected]

86+020-87342410

Wei-Hua Jia, MD

CONTACT

[email protected]

86+020-87342327

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Collaborators

  • First People's Hospital of Foshan

Registry information

Official study title

Genetic Susceptibility Study of Primary Pulmonary Lymphoepithelioma-like Carcinoma

Acronym: CPLCC

Important dates

Study start
2002
Primary completion
2025
Study completion
2030
First posted
Jan 30, 2025
Registry last updated
Jan 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.